Suppr超能文献

巨人的陨落与基因编辑的崛起:伦理、私人利益与公共利益。

Falling giants and the rise of gene editing: ethics, private interests and the public good.

机构信息

Department of Bioethics, Faculty of Medicine, Dalhousie University, Halifax, Canada.

School of Law, University of Manchester, Manchester, UK.

出版信息

Hum Genomics. 2017 Aug 29;11(1):20. doi: 10.1186/s40246-017-0116-4.

Abstract

This paper considers the tensions created in genomic research by public and private for-profit ideals. Our intent is to strengthen the public good at a time when doing science is strongly motivated by market possibilities and opportunities. Focusing on the emergence of gene editing, and in particular CRISPR, we consider how commercialisation encourages hype and hope-a sense that only promise and idealism can achieve progress. At this rate, genomic research reinforces structures that promote, above all else, private interests, but that may attenuate conditions for the public good of science. In the first part, we situate genomics using the aphorism that 'on the shoulders of giants we see farther'; these giants are infrastructures and research cultures rather than individual 'heroes' of science. In this respect, private initiatives are not the only pivot for successful discovery, and indeed, fascination in those could impinge upon the fundamental role of public-supported discovery. To redress these circumstances, we define the extent to which progress presupposes research strategies that are for the public good. In the second part, we use a 'falling giant' narrative to illustrate the risks of over-indulging for-profit initiatives. We therefore offer a counterpoint to commercialised science, using three identifiable 'giants'-scientists, publics and cultures-to illustrate how the public good contributes to genomic discovery.

摘要

本文探讨了公共和私营营利性理想在基因组研究中所产生的紧张关系。我们的意图是在科学受到市场可能性和机会强烈推动的时代,加强公共利益。本文聚焦于基因编辑的出现,特别是 CRISPR,考虑了商业化如何鼓励炒作和希望——一种只有承诺和理想主义才能取得进展的感觉。以这种速度,基因组研究强化了促进私人利益的结构,但可能会削弱科学公共利益的条件。在第一部分,我们用“站在巨人的肩膀上,我们看得更远”这句格言来定位基因组学;这些巨人是基础设施和研究文化,而不是科学的个别“英雄”。在这方面,私人倡议并不是成功发现的唯一支点,事实上,对这些发现的迷恋可能会影响到公共支持发现的基本作用。为了纠正这些情况,我们界定了进步在多大程度上需要以公共利益为导向的研究策略。在第二部分,我们使用“倒下的巨人”的叙述来说明过度放纵营利性倡议的风险。因此,我们提出了商业化科学的对立面,使用三个可识别的“巨人”——科学家、公众和文化——来说明公共利益如何为基因组学发现做出贡献。

相似文献

1
Falling giants and the rise of gene editing: ethics, private interests and the public good.
Hum Genomics. 2017 Aug 29;11(1):20. doi: 10.1186/s40246-017-0116-4.
2
Commit to talks on patient data and public health.
Nature. 2017 Aug 8;548(7666):137. doi: 10.1038/548137a.
3
Human genome editing: ask whether, not how.
Nature. 2019 Jan;565(7738):135. doi: 10.1038/d41586-018-07881-1.
4
The social aspects of genome editing: publics as stakeholders, populations and participants in animal research.
Lab Anim. 2022 Feb;56(1):88-96. doi: 10.1177/0023677221993157. Epub 2021 Feb 17.
5
A Q methodology study on divergent perspectives on CRISPR-Cas9 in the Netherlands.
BMC Med Ethics. 2021 Apr 26;22(1):48. doi: 10.1186/s12910-021-00615-5.
7
Guidelines, editors, pharma and the biological paradigm shift.
Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.
8
Science and the sources of hype.
Public Health Genomics. 2012;15(3-4):209-17. doi: 10.1159/000336533. Epub 2012 Apr 4.
9
Ethical issues of CRISPR technology and gene editing through the lens of solidarity.
Br Med Bull. 2017 Jun 1;122(1):17-29. doi: 10.1093/bmb/ldx002.
10
Credit for and Control of Research Outputs in Genomic Citizen Science.
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:465-489. doi: 10.1146/annurev-genom-083117-021812.

引用本文的文献

2
Commoning genomic solidarity to improve global health equality.
Cell Genom. 2023 Sep 28;3(10):100405. doi: 10.1016/j.xgen.2023.100405. eCollection 2023 Oct 11.
3
Review: Recent Applications of Gene Editing in Fish Species and Aquatic Medicine.
Animals (Basel). 2023 Apr 4;13(7):1250. doi: 10.3390/ani13071250.
4
Is Malaysia Ready for Human Gene Editing: A Regulatory, Biosafety and Biosecurity Perspective.
Front Bioeng Biotechnol. 2021 Mar 11;9:649203. doi: 10.3389/fbioe.2021.649203. eCollection 2021.
5
DGK and DZHK position paper on genome editing: basic science applications and future perspective.
Basic Res Cardiol. 2021 Jan 15;116(1):2. doi: 10.1007/s00395-020-00839-3.
6
Genome Editing for Rare Diseases.
Curr Stem Cell Rep. 2020 Sep;6(3):41-51. doi: 10.1007/s40778-020-00175-1. Epub 2020 Jul 7.
8
Where Does Open Science Lead Us During a Pandemic? A Public Good Argument to Prioritize Rights in the Open Commons.
Camb Q Healthc Ethics. 2021 Jan;30(1):11-24. doi: 10.1017/S0963180120000456. Epub 2020 Jun 5.
9
Germline genome editing: public dialogue is urgent but not self-evident.
Eur J Hum Genet. 2020 Jan;28(1):4-5. doi: 10.1038/s41431-019-0474-6. Epub 2019 Jul 22.
10
Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases.
Mol Diagn Ther. 2019 Apr;23(2):201-222. doi: 10.1007/s40291-019-00392-3.

本文引用的文献

1
Ethical issues of CRISPR technology and gene editing through the lens of solidarity.
Br Med Bull. 2017 Jun 1;122(1):17-29. doi: 10.1093/bmb/ldx002.
2
Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.
J Bioeth Inq. 2017 Jun;14(2):261-273. doi: 10.1007/s11673-017-9776-y. Epub 2017 Feb 28.
3
Industry sponsorship and research outcome.
Cochrane Database Syst Rev. 2017 Feb 16;2(2):MR000033. doi: 10.1002/14651858.MR000033.pub3.
4
The commercialization of genome-editing technologies.
Crit Rev Biotechnol. 2017 Nov;37(7):924-932. doi: 10.1080/07388551.2016.1271768. Epub 2017 Jan 18.
5
Overview of CRISPR-Cas9 Biology.
Cold Spring Harb Protoc. 2016 Dec 1;2016(12):pdb.top088849. doi: 10.1101/pdb.top088849.
6
The emerging patent landscape of CRISPR-Cas gene editing technology.
Nat Biotechnol. 2016 Oct 11;34(10):1025-1031. doi: 10.1038/nbt.3692.
7
8
Can a good tree bring forth evil fruit? The funding of medical research by industry.
Br Med Bull. 2016 Jun;118(1):5-15. doi: 10.1093/bmb/ldw014. Epub 2016 May 5.
9
The Heroes of CRISPR.
Cell. 2016 Jan 14;164(1-2):18-28. doi: 10.1016/j.cell.2015.12.041.
10
Models of biobanks and implications for reproductive health innovation.
Monash Bioeth Rev. 2015 Dec;33(4):238-57. doi: 10.1007/s40592-015-0042-y.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验